Close mobile menu×
Close mobile menu

Andrew B. Lassman, MD

Board Certifications: 
Neurology
Expertise in: 
Neuro-Oncology, Cancer Care, Brain & Spinal Tumors
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 342-0571

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Neurology

Clinical Expertise

  • Neuro-Oncology
  • Cancer Care
  • Brain & Spinal Tumors
  • Acoustic Neuroma
  • Astrocytoma
  • Anaplastic Astrocytoma
  • Brain Tumor
  • Brain Metastases
  • Brain Stem Glioma
  • Brain Cancer
  • Carcinomatous meningitis
  • Chordoma
  • Choroid Plexus Papilloma
  • Choroid Plexus Carcinoma
  • Ependymoma
  • Gliomas
  • Glioblastoma
  • Glioblastoma Multiforme
  • Hemangioblastoma
  • Leptomeningeal metastases
  • Medulloblastoma
  • Meningioma
  • Metastatic Cancer
  • Mixed Glioma
  • Neurofibromatosis
  • Oligodendroglioma
  • Oligoastrocytoma
  • Second Opinion
  • Spinal Cord Tumor
  • Spinal Tumors

Specialties

Education & Training

  • MD, Columbia University College of Physicians and Surgeons
  • Internship: Mount Sinai Hospital
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Honors & Awards

  • Neurology Resident Teaching Award, Memorial Sloan-Kettering Cancer Center/Weill Medical College of Cornell University
  • Preuss Award in Neuro-Oncology, American Academy of Neurology
  • Boyer Clinical Research Award, Memorial Sloan-Kettering Cancer Center
  • Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer

About Andrew Lassman

Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University Irving Medical Center and serves as the Associate Director for Clinical Trials at the Herbert Irving Comprehensive Cancer Center. His research and clinical efforts focus on improving the understanding and treatment of brain tumors. Specifically, his research interests focus on translational clinical trials for brain tumors with molecular correlative analyses to understand the reasons for treatment success or failure, and to refine treatment paradigms. Dr. Lassman has led retrospective studies, single institution prospective clinical trials, and multicenter prospective trials conducted nationally through the National Cancer Institute sponsored National Clinical Trials Network. His contributions to the field of neuro-oncology has been recognized with numerous awards, including the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. Dr. Lassman earned his BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, and went on to received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.

Academic Titles

  • John Harris Associate Professor of Neurology

Administrative Positions

  • Chief, Division of Neuro-Oncology
  • Co-Director, Brain Tumor Center
  • Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center

Committee/Societies/Council Memberships

American Medical Association, Member

American Academy of Neurology, Member

Society for Neuro-Oncology, Member

American Society of Clinical Oncology, Member

Radiation Therapy Oncology Group, Brain Committee

Society for Neuro-Oncology, Annual Meeting, Abstract Review Committee

NIH Common Terminology Criteria for Adverse Events (CTCAE) Revision Committee

United Council for Neurologic Subspecialties Board, Neuro-Oncology Representative

Voices Against Brain Cancer Medical Advisory Board

American Society of Clinical Oncology, Scientific Program Committee, CNS Track

American College of Radiation Oncology, Scientific Program Committee

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO
  • The Empire Plan (NYSHIP)

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
710 West 168th Street
New York, New York 10032
Phone:
(212) 342-0571
Fax:
(212) 342-1246
Primary

Research

Dr. Lassman's research interests focus on translational clinical trials for brain tumors with molecular correlative analyses to understand the reasons for treatment success or failure, and to refine treatment paradigms.

Research Interests

  • Translational clinical trials for brain tumors
  • Brain and leptomeningeal metastases

Clinical Trials

Multiple clinical trials for patients with brain tumors metastases

Grants

A PHASE 1B/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF BGB-290 IN COMBINATION WITH RADIATION THERAPY AND/OR TEMOZOLOMIDE IN SUBJECTS WITH FIRST-LINE OR RECURRENT/REFRACTORY GLIOBLASTOMA (P&S Industry Clinical Trial)

Aug 30 2018 - Aug 30 2023

EGFR AND RELATE BIOMARKERS N GBM, CONCORDANCE ACROSS METHODS AND MAINTENANCE OVER DISEASE ARC. (P&S Industry Clinical Trial)

Jul 13 2018 - Jul 13 2023

PHASE 3B STUDY FOR MANAGEMENT OF OCULAR SIDE EFFECTS IN SUBJECTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN (ABT-414) (P&S Industry Clinical Trial)

Jul 9 2018 - Jul 9 2023

SERVICE AGREEMENT: A TWO-PART, PHASE I/IIA DOSE-ESCALATION CLINICAL TRAIL TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN (P&S Industry Clinical Trial)

Dec 6 2017 - Dec 6 2022

A TWO-PART, PHASE I/IIA DOSE-ESCALATION STUDY TO DEFINE THE SAFETY, TOLERABILITY, AND OPTIMAL DOSE OF CANDIDATE GBM VACCINE VBI-1901 WITH SUBSEQUENT EXTENSION OF OPTIMAL DOSE IN RECURRENT GBM SUBJECTS. (P&S Industry Clinical Trial)

Nov 29 2017 - Nov 29 2022

GBM AGILE GLOBAL ADAPTIVE TRIAL MASTER PROTOCOL (Private)

Jun 11 2019 - Jun 10 2022

A STUDY OF RADIOLOGICALLY EVIDENT TREATMENT EFFECTS IN SUBJECTS WITH GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)

May 15 2017 - May 15 2022

A PHASE 2, MULTICENTER STUDY OF TESEVATINIB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

Apr 18 2017 - Apr 18 2022

A PHASE II, OPEN LABEL, MULTI-CENTER STUDY IN ADULTS WITH RECURRENT HIGH GRADE GLIOMA (Federal Gov)

Apr 9 2019 - Apr 8 2022

PHASE I/II DOSE ESCALATION TRIAL TO ASSESS SAFETY OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)

Feb 4 2015 - Feb 4 2020

PHASE II TRIAL OF VELCADE? (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

Dec 11 2014 - Dec 11 2019

COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)

Aug 1 2014 - Jul 31 2019

A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE FAILED WHOLE BRAIN RADIATION THERAPY (P&S Industry Clinical Trial)

Jul 18 2014 - Jul 18 2019

IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)

Jul 15 2016 - Jun 30 2019

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2019

A PHASE II, TWO TIER STUDY EVALUATING THE EFFICACY AND SAFETY OF SELINEXOR (KPT 330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA AFTER FAILURE OF RADIATION THERAPY AND TEMOZOLOMIDE (P&S Industry Clinical Trial)

Jun 20 2014 - Jun 20 2019

A PHASE IB/II, OPEN LABEL, MULITCENTER STUDY OF INC280 IN COMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

May 14 2014 - May 14 2019

A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF BGJ398 IN PATIENTS WITH RECURRENT RESECTABLE OR UNRESECTABLE GLIOBLASTOMA (P&S Industry Clinical Trial)

Mar 4 2014 - Mar 4 2019

A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA (P&S Industry Clinical Trial)

Oct 2 2013 - Oct 2 2018

A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ABT-414 IN COMBINATION WITH RADIATION PLUS TEMOZOLOMIDE OR TEMOZOLOMIDE ALONE (P&S Industry Clinical Trial)

Aug 13 2013 - Aug 13 2018

AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)

Jul 26 2013 - Jul 26 2018

PHASE II STUDY OF AMG 386 WITH AND WITHOUT BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

Apr 23 2013 - Apr 23 2018

PILOT STUDY OF EGFR INHIBITION USING HIGH DOSE ADMINISTRATION OF ERLOTINIB WEEKLY FOR RECURRENT MALIGNANT GLIOMAS WITH EGFR VARIANT III MUTATION - PILOT STUDY OF EGFR INHIBITION FOR GMB (P&S Industry Clinical Trial)

Jan 10 2013 - Jan 10 2018

CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION (INTELLANCE 1) (RTOG 3508) (Private)

Sep 1 2015 - Aug 31 2016

A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENTGLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

Jan 5 2011 - Jan 5 2016

PHASE II CLINICAL TRIAL OF PERIFOSINE + TEMSIROLIMUS FOR RECURRENT GLIOBLASTOMA WITH TISSUE AND IMAGING CORRELATES OF RESPONSE (Private)

Jan 1 2013 - Dec 31 2015

COLUMBIA UNIVERSITY MEDICAL CENTER MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (MB-CCOP) (Federal Gov)

Aug 6 2012 - May 31 2015

RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)

Jan 1 2009 - Dec 31 2014

PULSATILE KINASE INHIBITOR THERAPY FOR MALIGNANT GILOMA: PROOF OF CONCEPT CLINICAL TRIAL (Private)

Jun 1 2013 - May 31 2014